MedTrace Logo

Optimization of the Patient Care Pathway in Immuno-oncology

NCT03329755 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2021-02-24

No results posted yet for this study

Summary

This study compares the care pathway of melanoma patients treated by immunotherapy in two ambulatory care structures. The aim is to measure if a care structure specialized in immuno-oncology could rationalize the care of patients.

This protocol will be based on two different follow-up during the treatment period:

* dedicated and coordinated e-follow-up (IUCT-O in Toulouse)
* standard follow-up (University Hospital Center in Bordeaux)

Patients will be followed from the first cycle of immunotherapy until 3 months after the initiation treatment.

Conditions

Interventions

OTHER

Dedicated and coordinated e-follow-up during the treatment period

* Completion of questionnaires using an electronic tool * Telephone follow-up between the nurse and the patient * Completion of the Quality of Life Questionnaire Core 30 (QLQ-C30)

OTHER

Standard follow-up during the treatment period

\- Completion of the Quality of Life Questionnaire Core 30 (QLQ-C30)

Sponsors & Collaborators

  • Institut Claudius Regaud

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-26
Primary Completion
2021-02-19
Completion
2021-02-19

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03329755 on ClinicalTrials.gov